Form 4: TransMedics Group Executive Tamer Khayal Reports Acquisition of Stock and Options

Tamer Khayal, Chief Commercial Officer of TransMedics Group, reports the acquisition of restricted stock units and stock options, along with adjustments to beneficial ownership.

Summary

• On February 23, 2024, Tamer Khayal, Chief Commercial Officer of TransMedics Group, acquired 12,127 restricted stock units (RSUs) and 18,690 stock options.
• The RSUs represent a contingent right to receive one share of TransMedics Group's common stock each.
• The stock options vest monthly at a rate of 2.0833% starting February 23, 2024, and will be fully vested by February 23, 2028, contingent upon continued service.
• Following these transactions, Khayal directly owns 26,502 shares of common stock.
• Khayal also indirectly owns 14,776 shares through the Khayal Family 2021 Irrevocable Trust and 11,051 shares through the Tamer Ibrahim Ahmed Khayal Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating executive compensation adjustments. The acquisition of stock and options can be seen as a positive sign of confidence, but it's not overwhelmingly positive.

Positives

• The acquisition of RSUs and stock options by a key executive signals confidence in the company's future performance.
• The vesting schedule of the stock options incentivizes long-term commitment from the executive.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Comparison to Industry Standards

• Executive compensation packages often include a mix of salary, stock options, and restricted stock units to align executive interests with shareholder value.
• Vesting schedules for stock options are common and typically range from three to five years.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the executive's increased stake in the company.

Key Dates